RXRX

6.10

1.21% -0.075

Handel nachbörslich: 6.16 0.06 +0.98%

Recursion Pharmaceuticals Inc (RXRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RXRX? Forum Prognose

Schlusskurs vom Vortag:

$6.175

Offen:

$6.25

24-Stunden-Volumen:

10.40M

Relative Volume:

2.06

Marktkapitalisierung:

$1.75B

Einnahmen:

$43.88M

Nettoeinkommen (Verlust:

$-328.07M

KGV:

-4.4203

EPS:

-1.38

Netto-Cashflow:

$-300.33M

1W Leistung:

-22.19%

1M Leistung:

-12.10%

6M Leistung:

-35.24%

1J Leistung:

-13.48%

1-Tages-Spanne:

$5.90

$6.26

1-Wochen-Bereich:

$5.90

$8.045

52-Wochen-Spanne:

$5.885

$15.74

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Firmenname

Recursion Pharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(385) 269-0203

Adresse

41S RIO GRANDE STREET, SALT LAKE CITY

Mitarbeiter

500

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

RXRX's Discussions on Twitter

Vergleichen Sie RXRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RXRX	6.10	1.75B	43.88M	-328.07M	-300.33M	-1.38
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-05-22	Eingeleitet	Morgan Stanley	Equal-Weight
2023-03-16	Eingeleitet	Needham	Buy
2022-09-16	Eingeleitet	KeyBanc Capital Markets	Overweight
2022-04-18	Herabstufung	BofA Securities	Buy → Neutral
2022-03-04	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-09-21	Eingeleitet	Berenberg	Buy
2021-05-11	Eingeleitet	BofA Securities	Buy
2021-05-11	Eingeleitet	Goldman	Neutral
2021-05-11	Eingeleitet	JP Morgan	Neutral
2021-05-11	Eingeleitet	KeyBanc Capital Markets	Overweight
2021-05-11	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten

Nov 15, 2024

Recursion Pharmaceuticals CEO sells $301,800 in stock - Investing.com

Nov 15, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling - MarketBeat

Nov 15, 2024

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com

Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Trims Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stock - Investing.com

Nov 14, 2024

Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stock - Investing.com

Nov 14, 2024

Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Nov 14, 2024

Nov 13, 2024

Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com

Nov 13, 2024

Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK

Nov 13, 2024

Recursion, Exscientia shareholders back merger - Investing.com

Nov 13, 2024

Recursion and Exscientia Shareholders Approve the Proposed Combination - The Manila Times

Nov 13, 2024

Recursion & Exscientia Merger Approved: AI Drug Discovery Giants Set to Unite | RXRX Stock News - StockTitan

Nov 13, 2024

Recursion releases OpenPhenom-S/16 for microscopy data By Investing.com - Investing.com Australia

Nov 13, 2024

FMR LLC's Strategic Acquisition in Recursion Pharmaceuticals Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Recursion releases OpenPhenom-S/16 for microscopy data - Investing.com

Nov 12, 2024

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden - GlobeNewswire

Nov 12, 2024

Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud?s Model Garden - Marketscreener.com

Nov 12, 2024

Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings - MarketBeat

Nov 11, 2024

Nov 10, 2024

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - Simply Wall St

Nov 10, 2024

Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - Yahoo Finance

Nov 10, 2024

Nov 08, 2024

ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Nov 08, 2024

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk - Simply Wall St

Nov 08, 2024

Nov 07, 2024

A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals - Benzinga

Nov 07, 2024

Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Nov 07, 2024

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 07, 2024

Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks

Nov 07, 2024

Nov 06, 2024

Recursion Pharmaceuticals: Q3 Earnings Snapshot - Barchart

Nov 06, 2024

Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 06, 2024

Recursion Pharmaceuticals Inc Cl A (RXRX-Q) QuotePress Release - The Globe and Mail

Nov 06, 2024

Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - AOL

Nov 06, 2024